Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 17.62%74.04B | 6.26%276.81B | 12.83%71.14B | 10.13%74.38B | 0.74%68.35B | 1.40%62.95B | 9.74%260.5B | -0.75%63.05B | 6.42%67.54B | 21.61%67.84B |
Cost of revenue | 16.64%41.34B | 3.64%154.12B | 10.32%41.13B | 8.23%40.21B | -2.75%37.33B | -1.22%35.44B | 7.60%148.71B | -0.68%37.28B | 3.87%37.16B | 18.28%38.39B |
Gross profit | 18.88%32.7B | 9.74%122.69B | 16.46%30B | 12.44%34.16B | 5.29%31.01B | 5.00%27.51B | 12.72%111.8B | -0.85%25.76B | 9.70%30.38B | 26.25%29.46B |
Operating expense | 11.80%27.59B | 7.34%107.95B | 9.02%29.41B | 5.22%28.18B | 8.28%25.68B | 6.89%24.68B | 11.23%100.56B | 13.79%26.97B | 8.63%26.78B | 10.85%23.71B |
Operating profit | 80.77%5.11B | 31.19%14.74B | 149.05%595M | 66.21%5.98B | -7.07%5.34B | -9.05%2.82B | 28.10%11.23B | -153.27%-1.21B | 18.39%3.6B | 195.88%5.74B |
Net non-operating interest income (expenses) | -1.76%-231M | -1.91%-958M | 15.04%-226M | -29.22%-283M | 10.84%-222M | -10.19%-227M | -13.39%-940M | -29.13%-266M | -7.35%-219M | -19.71%-249M |
Non-operating interest income | 20.43%112M | 96.98%392M | 58.46%103M | 47.30%109M | 163.64%87M | 244.44%93M | 197.01%199M | 333.33%65M | 335.29%74M | 50.00%33M |
Non-operating interest expense | 7.19%343M | 18.53%1.35B | -0.60%329M | 33.79%392M | 9.57%309M | 37.34%320M | 27.12%1.14B | 49.77%331M | 32.58%293M | 22.61%282M |
Net investment income | -27.36%701M | 24.64%961M | 0 | 42.26%-153M | 60.22%149M | 2.33%965M | -0.39%771M | 0 | -180.30%-265M | 60.34%93M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 125.36%139M | 0 | -548M | -548M | ||||||
Income from associates and other participating interests | 13.48%1.39B | 32.08%597M | -1.19%166M | 22.65%287M | -8.38%339M | 36.30%1.22B | -16.14%452M | -14.29%168M | 75.94%234M | |
Special income (charges) | 6.96%-909M | 98.40%-12M | -606.36%-777M | -1,614.29%-120M | 0 | 8.00%-977M | -250.93%-751M | -1,933.33%-110M | 98.31%-7M | |
Less:Restructuring and mergern&acquisition | ---- | 1.55%983M | -42.19%481M | 443.64%598M | ---- | ---- | 338.01%968M | 276.47%832M | --110M | ---- |
Less:Other special charges | ---- | -9,877.78%-880M | -1,474.07%-1.28B | --179M | ---- | ---- | -98.93%9M | -1,057.14%-81M | --0 | -104.58%-19M |
Less:Write off | ---- | --806M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
Other non-operating income (expenses) | 4.71%-162M | 78.97%-236M | 24.71%-393M | 371.64%364M | 87.99%-37M | -7.59%-170M | -445.23%-1.12B | -501.54%-522M | -148.73%-134M | -100.00%-308M |
Income before tax | 45.10%5.42B | 56.85%15.12B | 119.70%561M | 78.75%5.43B | -1.94%5.4B | -5.45%3.73B | 8.63%9.64B | -212.66%-2.85B | -16.51%3.04B | 306.13%5.5B |
Income tax | 49.56%1.69B | 10.10%4.79B | 595.18%1.15B | 449.73%1.02B | -21.61%1.48B | -46.24%1.13B | 91.96%4.35B | 5,633.33%166M | -79.17%185M | 792.92%1.89B |
Net income | 43.18%3.72B | 95.24%10.34B | 80.36%-592M | 54.77%4.42B | 8.34%3.91B | 41.05%2.6B | -19.91%5.3B | -219.08%-3.01B | 3.71%2.85B | 215.92%3.61B |
Net income continuous operations | 43.16%3.73B | 95.20%10.34B | 80.33%-593M | 54.71%4.42B | 8.37%3.91B | 41.03%2.6B | -19.90%5.3B | -219.08%-3.01B | 3.71%2.86B | 215.84%3.61B |
Noncontrolling interests | 21.58%231M | 7.12%286M | -101.61%-1M | 27.91%55M | 61.54%42M | 39.71%190M | 36.22%267M | 138.46%62M | 22.86%43M | 766.67%26M |
Net income attributable to the company | 44.84%3.49B | 99.90%10.05B | 80.75%-592M | 55.12%4.36B | 7.95%3.87B | 41.24%2.41B | -21.62%5.03B | -222.79%-3.08B | 3.50%2.81B | 214.47%3.59B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 44.84%3.49B | 99.90%10.05B | 80.75%-592M | 55.12%4.36B | 7.95%3.87B | 41.24%2.41B | -21.62%5.03B | -222.79%-3.08B | 3.50%2.81B | 214.47%3.59B |
Gross dividend payment | ||||||||||
Basic earnings per share | 46.60%85.66 | 100.50%244.33 | 81.72%-13.63 | 55.31%105.83 | 7.84%93.7 | 41.14%58.43 | -21.66%121.86 | -222.75%-74.57 | 3.43%68.14 | 214.48%86.89 |
Diluted earnings per share | 46.60%85.66 | 100.50%244.33 | 80.53%-14.5225 | 55.31%105.83 | 7.84%93.7 | 41.14%58.43 | -21.66%121.86 | -222.75%-74.57 | 3.43%68.14 | 214.48%86.89 |
Dividend per share | 0 | 6.67%80 | 13.33%42.5 | 0 | 0.00%37.5 | 0 | 50.00%75 | 50.00%37.5 | 0 | 50.00%37.5 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |